Topiramate Tablet, Film Coated
Product Images NDC 60760-075

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 60760-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Top (Topiramate 60760 075 60)

Top (Topiramate 60760 075 60)
This is useful description for a medication named "Topiramate Tablets, USP". The National Drug Code (NDC) for the medication is "60760-075-60". The medication is available in a pack of 60 tablets with a concentration of 25mg each. The manufactured of the medication is "Cadila Healthcare Ltd. Ahmedabad, India". The medication should be used as directed and stored at a controlled room temperature ranging from 15°- 30° C (53°-86°F). However, some details like RX number has been blurred and are not available.*
FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 01)

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 02)

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 02)
This is a chart (Figure 1) showing the Kaplan-Meier Estimates of Cumulative Rates for Time to First Seizure. There are two groups represented: one group of 234 people taking Topiramate 50 mg/day and another group of 236 people taking Topiramate 400 mg/day. The x-axis represents time in days and the y-axis represents the cumulative percentage of people who have not had a seizure.*
FDA Label Image

Topiramate Tablets Usp (A9eed983 Edf1 4f44 A8ec 568a52f03015 03)

Topiramate Tablets Usp (A9eed983 Edf1 4f44 A8ec 568a52f03015 03)
The text presents data on the change in average monthly migraine period rate from baseline to double-blind phase for topiramate and placebo at different doses. The results are presented using a table with the sample size and standard error. The asterisks indicate statistical significance.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.